Literature DB >> 30311866

Clinical differences of early and late-onset myasthenia gravis in 985 patients.

Lingling Fan1, Shan Ma1, Yongxiang Yang2,3, Zhongjun Yan4, Junchao Li1, Zhuyi Li5.   

Abstract

Objective: The clinical differences of early-onset myasthenia gravis (EOMG) and late-onset MG (LOMG) have not been elucidated in China. In order to clarify this, a retrospective study was conducted in 985 MG patients, whose disease duration was longer than 3 years.
Methods: These patients were separated into EOMG and LOMG according to the onset age of 50 years. The clinical differences including demographics, clinical features, thymus abnormalities and comorbidities of EOMG and LOMG patients were analyzed.
Results: Results indicated that 485 were males and 500 were females, 714 were EOMG and 271 were LOMG. Female was more common in EOMG and male was more common in LOMG (p = 0.003). The peak onset age was 0-4 years in EOMG and 55-59 years in LOMG. Ocular MG (OMG) was more common in EOMG and generalized MG (GMG) was more common in LOMG (p = 0.004). The transformation rate of OMG to GMG was higher in LOMG (p = 0.002). The positive incidence of repetitive nerve stimulation (RNS) was higher in EOMG (p = 0.026). Thymoma was more frequent in LOMG (p = 0.017) and thymic hyperplasia was more frequent in EOMG (p < 0.001). Hyperthyroidism was more common in EOMG (p = 0.017) and diabetes was more common in LOMG (p < 0.001).
Conclusion: These results have potential significance for the recognition of clinical features and the determination of management strategies in EOMG and LOMG.

Entities:  

Keywords:  Clinical differences; early-onset myasthenia gravis(EOMG); late-onset myasthenia gravis(LOMG)

Year:  2018        PMID: 30311866     DOI: 10.1080/01616412.2018.1525121

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  5 in total

1.  Soy isoflavones ameliorate the cognitive dysfunction of Goto-Kakizaki rats by activating the Nrf2-HO-1 signalling pathway.

Authors:  Boxi Ke; Tianmeng Zhang; Tianyang An; Rong Lu
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

2.  Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis.

Authors:  Mingxia Li; Fangfang Ge; Rongjing Guo; Zhe Ruan; Yanwu Gao; Chunxiao Niu; Hong Lin; Zhengwei Zhao; Yongan Zhou; Zhuyi Li; Ting Chang
Journal:  Ther Adv Neurol Disord       Date:  2019-09-14       Impact factor: 6.570

3.  Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.

Authors:  Sijia Zhao; Xu Yan; Jiaqi Ding; Kaixi Ren; Shuyu Sun; Jiarui Lu; Chao Zhang; Kai Zhang; Zhuyi Li; Jun Guo
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

4.  Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility.

Authors:  Hui Deng; Jianjian Wang; Xiaotong Kong; Huixue Zhang; Tianfeng Wang; Wenqi Tian; Tingting Yi; Lihua Wang
Journal:  BMC Med Genet       Date:  2019-10-30       Impact factor: 2.103

5.  No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.

Authors:  Lulu Wang; Shumin Wang; Haonan Yang; Jiaojiao Han; Xue Zhao; Sensen Han; Yingna Zhang; Jie Lv; Jing Zhang; Mingqiang Li; Ying Ji; Shuxian Zhou; Xiaoxiao He; Hua Fang; Junhong Yang; Yunke Zhang; Qingyong Zhang; Peiyang Gao; Feng Gao
Journal:  Brain Behav       Date:  2021-06-02       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.